chicago ASCO 2019
By setting new facilities within the cancer center “Institut Bergonié”, Explicyte strengthens its development towards clinical translational research, to provide new services based on multiparametric experimental biomarker analysis, for target identification and monitoring of the immune response in the context of clinical trials.
immune profiling syngeneic tumor models services CRO
Syngeneic tumor models are becoming invaluable for preclinical development and evaluation of immuno-based therapies. They are primordial for tumor model characterization and selection of the appropriate ones, for target validation, drug development, and assessment of the efficacy potential of drug candidates.
MODIFY NK EUROSTARS
Eurostars, a European joint programme, co-funded from the national budgets of several EUREKA countries and by the European Union through Horizon 2020 has awarded, through a highly-competitive selection process, the Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK.
immune cell activation assay
Modulation of the immune system function aiming at enhancing the responsiveness potential of immune cells is one of the current promising challenges in cancer immunotherapy. Modulating the mechanisms underlying immune cell activation is key for the development of innovative approaches to promote immune function and tackle tumor progression.
WordPress Lightbox